Amgen's earnings call highlighted strong Q4 and full-year 2020 performance, driven by volume growth and successful pipeline advancements like sotorasib, tezepelumab, and the integration of Otezla.  Management is optimistic about the future, with a focus on capitalizing on the growing oncology market while addressing potential pressure on drug prices.  The call generally conveys strong confidence in the company's future trajectory, and anticipates a continued expansion into new markets and therapies.
[2]
